ArticleJournal of applied toxicology : JAT2026
Mechanistic Evaluation of Chlorfenapyr-Induced Hepatotoxicity and the Mitigating Actions of Resveratrol-Loaded Chitosan Nanoparticles.
Article in Journal of applied toxicology : JAT, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nano-Rosmarinic Acid Protects Against Chlorfenapyr-Induced Testicular Toxicity Through Modulation of NRF2/HO-1 and NF-κB/NLRP3 Signaling Pathways.Journal of biochemical and molecular toxicology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chlorfenapyr (CFP) is an insecticide known to induce hepatotoxicity through oxidative stress, inflammation, and mitochondrial dysfunction. Resveratrol (RES) exhibits antioxidant and anti-inflammatory properties, and its delivery via chitosan nanoparticles (RES-CNPs) may enhance its protective effects. This study aimed to investigate the hepatoprotective potential of RES and RES-CNPs against CFP-induced liver damage in Wistar rats. Sixty male Wistar rats were randomly divided into six groups (n = 10): control, RES, RES-CNPs, CFP, CFP + RES, and CFP + RES-CNPs. Treatments were administered orally for 30 days. Liver function, lipid profile, oxidative stress markers, antioxidant defense system, energy metabolism, mitochondrial function, inflammatory gene expression, histopathology, and ultrastructure were evaluated exposure significantly decreased total protein, albumin, antioxidant levels (GSH, CAT, SOD, GPX), ATP, and PDH activity, while increasing liver enzymes (AST, ALT, ALP), lipid peroxidation (MDA, PCO), mitochondrial dysfunction, inflammatory gene expression (NF-κB, TNF-α, IL-6), CRP, and total leukocyte count (p < 0.05). Co-administration of RES-CNPs significantly restored these biochemical, molecular, and histological parameters, showing superior efficacy to crude RES in most endpoints and achieving values close to the negative control for several markers (p > 0.05). Histopathological and ultrastructural analyses confirmed CFP-induced hepatocyte degeneration and necrosis, which were ameliorated by RES-CNPs, with near-normal liver architecture and cellular integrity. RES-CNPs effectively mitigate CFP-induced hepatotoxicity by restoring liver function, enhancing antioxidant defenses, preserving mitochondrial function, and suppressing inflammation. RES-CNPs demonstrated superior hepatoprotective effects compared to crude RES, highlighting their potential as a therapeutic strategy against xenobiotic-induced liver injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.